Linked Life Data

11032948

Source:http://linkedlifedata.com/resource/pubmed/id/11032948

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-10-25
pubmed:abstractText
Epidemiological and experimental studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) reduce the relative risk of human cancer, including breast cancer. Recently, research studies in our laboratories have shown that the selective cyclooxygenase-2 (COX-2) blocker, Celecoxib, given daily in the diet, significantly inhibited the induction of rat mammary tumors by 7, 12-dimethylbenz(a)anthracene (DMBA). These studies were extended to evaluate Celecoxib for its effectiveness as an antineoplastic agent in this rat mammary tumor model. We examined the growth inhibitory effects of Celecoxib, given daily in the diet, on the volume and the number of established mammary tumors, vis-a-vis the cancer load (CL). Tumors continued to grow actively in control rats fed chow diet only. In contrast, the Celecoxib-supplemented diet (1500 mg/kg diet) significantly decreased the size of the mammary tumors in rats over the 6 week treatment period, resulting in an average reduction in tumor volume of approximately 32%, relative to the baseline volume (p<0.04). At the end of the 6 week treatment period, average tumor volume was 1.45 cm3 and 0.13 cm3 in the control and Celecoxib treated rats respectively. Tumor regression occurred in 90% of the rats. In addition, new tumors continued to emerge in the control group, in contrast to their significantly decreasing numbers in the Celecoxib treated group over the same time period (p<0.05). These results indicate that Celecoxib has significant antineoplastic activity, in addition to its anticarcinogenic effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1021-335X
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1377-81
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11032948-9,10-Dimethyl-1,2-benzanthracene, pubmed-meshheading:11032948-Adenocarcinoma, pubmed-meshheading:11032948-Animals, pubmed-meshheading:11032948-Antineoplastic Agents, pubmed-meshheading:11032948-Body Weight, pubmed-meshheading:11032948-Carcinogens, pubmed-meshheading:11032948-Cyclooxygenase 2, pubmed-meshheading:11032948-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:11032948-Cyclooxygenase Inhibitors, pubmed-meshheading:11032948-Eating, pubmed-meshheading:11032948-Female, pubmed-meshheading:11032948-Isoenzymes, pubmed-meshheading:11032948-Mammary Neoplasms, Experimental, pubmed-meshheading:11032948-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:11032948-Pyrazoles, pubmed-meshheading:11032948-Rats, pubmed-meshheading:11032948-Rats, Sprague-Dawley, pubmed-meshheading:11032948-Sulfonamides
pubmed:articleTitle
Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model.
pubmed:affiliation
School of Public Health, The Ohio State University, College of Medicine and Public Health, Columbus, OH 43210, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't